SHP Wealth Management’s Royalty Pharma RPRX Stock Holding History

SHP Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$439	Hold	9	–	–	﹤0.01%	1644
2025 Q4	$352	Buy	+9	New	+$343	﹤0.01%	1403

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SHP Wealth Management's RPRX Position: Q1 2026 in Review

SHP Wealth Management held its Royalty Pharma (RPRX) position steady in Q1 2026 at 9 shares worth $439. The position accounts for ﹤0.01% of the portfolio, ranked #1644.

SHP Wealth Management first reported a position in RPRX in Q4 2025 and has held it in 2 quarters since. 590 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

SHP Wealth Management held 9 shares of Royalty Pharma worth $439 as of Q1 2026.
SHP Wealth Management left its Royalty Pharma share count unchanged in Q1 2026.
Royalty Pharma made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1644 holding.
SHP Wealth Management first reported a position in Royalty Pharma in Q4 2025 and has held it in 2 quarters since.
590 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.